76 related articles for article (PubMed ID: 28589759)
41. Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm.
Rampal R; Mascarenhas J
Curr Opin Hematol; 2014 Mar; 21(2):65-71. PubMed ID: 24366192
[TBL] [Abstract][Full Text] [Related]
42. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
Björkholm M; Hultcrantz M; Derolf ÅR
Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
[TBL] [Abstract][Full Text] [Related]
43. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
44. In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.
Greenberg PL
Clin Haematol; 1986 Nov; 15(4):973-93. PubMed ID: 3552351
[No Abstract] [Full Text] [Related]
45. Inflammation and myeloproliferative neoplasms.
Lussana F; Rambaldi A
J Autoimmun; 2017 Dec; 85():58-63. PubMed ID: 28669446
[TBL] [Abstract][Full Text] [Related]
46. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera.
Kvasnicka HM; Thiele J
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):362-71. PubMed ID: 16810612
[TBL] [Abstract][Full Text] [Related]
47. A clinical update in polycythemia vera and essential thrombocythemia.
Tefferi A; Solberg LA; Silverstein MN
Am J Med; 2000 Aug; 109(2):141-9. PubMed ID: 10967156
[TBL] [Abstract][Full Text] [Related]
48. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies.
Georgii A; Buhr T; Buesche G; Kreft A; Choritz H
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():15-29. PubMed ID: 8951769
[TBL] [Abstract][Full Text] [Related]
49. Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.
Tallarico M; Odenike O
Curr Hematol Malig Rep; 2015 Jun; 10(2):112-7. PubMed ID: 25893311
[TBL] [Abstract][Full Text] [Related]
50. Assessing disease burden in patients with classic MPNs.
Geyer H; Mesa RA
Best Pract Res Clin Haematol; 2014 Jun; 27(2):107-19. PubMed ID: 25189722
[TBL] [Abstract][Full Text] [Related]
51. How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
Titmarsh GJ; Duncombe AS; McMullin MF; O'Rorke M; Mesa R; De Vocht F; Horan S; Fritschi L; Clarke M; Anderson LA
Am J Hematol; 2014 Jun; 89(6):581-7. PubMed ID: 24971434
[TBL] [Abstract][Full Text] [Related]
52. Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development.
Geyer HL; Dueck AC; Scherber RM; Mesa RA
Mediators Inflamm; 2015; 2015():284706. PubMed ID: 26538823
[TBL] [Abstract][Full Text] [Related]
53. New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options.
Penna D
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833399
[TBL] [Abstract][Full Text] [Related]
54. Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.
Noor SJ; Tan W; Wilding GE; Ford LA; Barcos M; Sait SN; Block AW; Thompson JE; Wang ES; Wetzler M
Leuk Res; 2011 May; 35(5):608-13. PubMed ID: 20727590
[TBL] [Abstract][Full Text] [Related]
55. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.
Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S124-9. PubMed ID: 27521308
[TBL] [Abstract][Full Text] [Related]
56. Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options.
Iurlo A; Cattaneo D; Gianelli U
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013941
[TBL] [Abstract][Full Text] [Related]
57. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia.
Johansson P
Semin Thromb Hemost; 2006 Apr; 32(3):171-3. PubMed ID: 16673273
[TBL] [Abstract][Full Text] [Related]
58. Hematopoietic stem cells (third of three parts).
Quesenberry P; Levitt L
N Engl J Med; 1979 Oct; 301(16):868-72. PubMed ID: 384249
[No Abstract] [Full Text] [Related]
59. Abnormal myelopoietic clones in man.
McCulloch EA
J Natl Cancer Inst; 1979 Oct; 63(4):883-92. PubMed ID: 384008
[No Abstract] [Full Text] [Related]
60. Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
Kundranda MN; Tibes R; Mesa RA
Curr Hematol Malig Rep; 2012 Mar; 7(1):78-86. PubMed ID: 22170483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
